Ionis to Present at Upcoming Investor Conferences

BusinesswireFeb 25 07:05 ET

Stifel Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $38

Moomoo NewsFeb 24 21:32 ET · Ratings

Stifel Nicolaus Remains a Hold on Ionis Pharmaceuticals (IONS)

TipRanksFeb 24 21:09 ET · Ratings

Insider Sale: EVP CLO & General Counsel of $IONS Sells 1,207 Shares

Quiver QuantitativeFeb 24 17:02 ET

Express News | Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $52 From $50

ReutersFeb 24 07:31 ET

Optimistic Future Outlook for Ionis Pharmaceuticals Driven by Robust Growth and Strategic Initiatives

TipRanksFeb 23 06:06 ET

Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $43

Moomoo NewsFeb 21 10:33 ET · Ratings

Ionis Pharmaceuticals Price Target Lowered to $60 From $61 at Raymond James

Yahoo FinanceFeb 21 09:35 ET

What Analysts Are Saying About Ionis Pharmaceuticals Stock

BenzingaFeb 20 17:03 ET

Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now

Yahoo FinanceFeb 20 12:14 ET

Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus

Zacks Feb 20 10:25 ET

Ionis Pharmaceuticals Is Maintained at Market Perform by BMO Capital

Dow JonesFeb 20 09:32 ET · Ratings

BMO Capital Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $45

Moomoo NewsFeb 20 08:31 ET · Ratings

RBC Capital Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $70

Moomoo NewsFeb 20 08:31 ET · Ratings

Citi Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Cuts Target Price to $64

Moomoo NewsFeb 20 08:31 ET · Ratings

A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $38 to $70

Moomoo NewsFeb 20 08:00 ET · Ratings

Express News | New Positive Donidalorsen Data to Be Presented at Aaaai/Wao Joint Congress Highlight Sustained Hae Attack Rate Reduction and Disease Control

ReutersFeb 20 07:00 ET

New Positive Donidalorsen Data to Be Presented at AAAAI/WAO Joint Congress Highlight Sustained HAE Attack Rate Reduction and Disease Control

BusinesswireFeb 20 07:00 ET

Ionis Pharmaceuticals: Balancing Strong R&D Revenues With Market Challenges – Hold Rating Justified

TipRanksFeb 20 06:47 ET · Ratings

Ionis Pharmaceuticals Price Target Lowered to $64 From $67 at Citi

TipRanksFeb 20 06:30 ET